Eli Lilly's LLY -0.28% Get Free Report short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly and Company (NYSE: LLY) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of ...

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Eli Lilly's market standing.

By 2023, the tone had shifted. Venture capital cooled. According to CB Insights, funding for AI drug discovery start-ups ...

We look at how the global impact investing market has experienced remarkable growth over the past decade, with emerging ...

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...